The solute family 1 member 5 is a protein encoded by the SLC1A5 gene in humans. It is also known as sodium-dependent neutral amino acid transporter type 2 (ASCT2). SLC1A5 appears to play an important role in the glutamate-glutamate cycle between neurons and glial cells by promoting the action of glutamine in glial cells. It is a major glutamine transporter that is highly expressed in a variety of malignancies and plays a crucial role in the transformation, growth and survival of cancer cells.
Basic Information of SLC1A5 | |
Protein Name | Neutral amino acid transporter B(0) |
Gene Name | SLC1A5 |
Aliases | Baboon M7 virus receptor, RD114/simian type D retrovirus receptor, Sodium-dependent neutral amino acid transporter type 2, Solute carrier family 1 member 5 |
Organism | Homo sapiens (Human) |
UniProt ID | Q15758 |
Transmembrane Times | 10 |
Length (aa) | 541 |
Sequence | MVADPPRDSKGLAAAEPTANGGLALASIEDQGAAAGGYCGSRDQVRRCLRANLLVLLTVVAVVAGVALGLGVSGAGGALALGPERLSAFVFPGELLLRLLRMIILPLVVCSLIGGAASLDPGALGRLGAWALLFFLVTTLLASALGVGLALALQPGAASAAINASVGAAGSAENAPSKEVLDSFLDLARNIFPSNLVSAAFRSYSTTYEERNITGTRVKVPVGQEVEGMNILGLVVFAIVFGVALRKLGPEGELLIRFFNSFNEATMVLVSWIMWYAPVGIMFLVAGKIVEMEDVGLLFARLGKYILCCLLGHAIHGLLVLPLIYFLFTRKNPYRFLWGIVTPLATAFGTSSSSATLPLMMKCVEENNGVAKHISRFILPIGATVNMDGAALFQCVAAVFIAQLSQQSLDFVKIITILVTATASSVGAAGIPAGGVLTLAIILEAVNLPVDHISLILAVDWLVDRSCTVLNVEGDALGAGLLQNYVDRTESRSTEPELIQVKSELPLDPLPVPTEEGNPLLKHYRGPAGDATVASEKESVM |
Glutamine enters the cell via the alanine/serine/cysteine transporter 2 (ASCT2) that is upregulated in several cancers to maintain an increased supply of this nutrient and are therefore an attractive target in cancer therapeutic development. SLC1A5 belongs to the glutamate transporter (SLC1A) family but is the only transporter in this family able to transport glutamine. SLC1A5 is expressed primarily outside the CNS. SLC1A5 was up-regulated in gastric cancer tissues and was correlated with malignant features such as deeper local invasion, higher lymph node metastasis, advanced TNM stages and higher Ki-67 expression.
Fig.1 The structure of SLC1A5 Protein.
These results suggest that SLC1A5 may be considered a novel biomarker and a potential therapeutic target for gastric cancer.
This article suggests that inhibition of SLC1A5 in cancer therapy can be tolerated by the immune system of cancer patients.
These results reveal that SLC1A5 may be considered as a new candidate biomarker for selective targeting of Gln-dependent NSCLC.
The research supports the fact that differential expression of human colorectal cancer and normal tissues, and a functional link between SLC1A5 expression and colorectal cancer growth and survival may be an attractive target for colorectal cancer treatment.
This article reveals that high SLC1A5 expression is an independent predictor of adverse clinical outcomes in patients with ccRCC.
To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC1A5 antibody development services.
Creative Biolabs' skillful scientists are glad to leverage our expertise and advanced technologies to help you with the member protein research. If you are interested, please feel free to contact us for more details.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.